RT Journal Article
SR Electronic
T1 Cost-effectiveness of switching from omalizumab to mepolizumab in uncontrolled severe eosinophilic asthma
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP 4809
DO 10.1183/13993003.congress-2020.4809
VO 56
IS suppl 64
A1 Resta, Emanuela
A1 Carpagnano, Giovanna Elisiana
A1 Pelaia, Corrado
A1 D'Amato, Maria
A1 Crimi, Nunzio
A1 Scichilone, Nicola
A1 Calabrese, Cecilia
A1 Resta, Onofrio
A1 Scioscia, Giulia
A1 Pelaia, Girolamo
A1 Foschino Barbaro, Maria Pia
YR 2020
UL http://erj.ersjournals.com/content/56/suppl_64/4809.abstract
AB Background: Severe asthma is burdened by frequent exacerbations and use of oral corticosteroids (OCS) which worsen patients’ quality of life and increased healthcare spending.Objectives: To assess the clinical and economic impact of switching from omalizumab (OMA) to mepolizumab (MEP) in patients eligible for both biologics but not optimally controlled with OMA.Methods: Uncontrolled patients referred to 6 asthma clinics in south of Italy switched from OMA to MEP, were enrolled and followed-up to Jan 2020. Clinical information included blood eosinophil count, asthma control test (ACT), pulmonary function, IgE, exhaled nitric oxide (FeNO), OCS intake, drugs, exacerbations/hospitalizations, visits and exams. A 12-months standardized total cost per patient pre and post MEP was calculated in the perspective of Italian National Health System.Results: 33 patients were enrolled: 5 male, median age 59 years, disease onset 24 years. At OMA discontinuation, 89% were OCS-dependent with annual mean rate of 3.1 exacerbations. The switch to MEP reduced both exacerbation (-2.8) and OCS-dependent patients (-76%). Pulmonary function improved and both IgE, FENO and eosinophils serum decreased. Annual cost was €11,277 with OMA and €12,498 with MEP (p=0.2041), the increment due to biologic (+€1,673) was partially offset by the saving due to all other cost items (-€452).Conclusions: Patients with severe eosinophilic asthma not controlled by OMA experienced a clinically benefit in asthma control switching to MEP with a slight economic impact.FootnotesCite this article as: European Respiratory Journal 2020; 56: Suppl. 64, 4809.This abstract was presented at the 2020 ERS International Congress, in session “Respiratory viruses in the "pre COVID-19" era”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).